Uterine Fibroids Market Global Analysis 2017 Global Uterine Fibroids Market Industry Analysis | Page 2

Uterine Fibroids Market Size, Application, Regional Outlook, Competitive
Strategies and Forecasts, 2017 to 2025
Uterine Fibroids Drugs Market is expected to experience robust growth post the launch of therapeutic
drugs, primarily due to increasing patient base, rise in female population, and increasing healthcare
expenditure. However, the market growth is hindered by high R&D costs and regulatory warnings.
Company Coverage of Global Uterine Fibroids Market: AbbVie, AstraZeneca, Neurocrine Biosciences,
Myovant Sciences Ltd. (Roivant Sciences, Ltd.).
Uterine Fibroids Market include increased focus on prophylactic treatment, growing market for FVIII,
increasing diagnosis rate, and increasing healthcare expenditure. Major trends of the market include
development of novel Uterine Fibroids treatment, subcutaneous dosing and growing popularity of gene
therapy. Further, growth prospects are hindered by high cost of therapy and consumer’s reluctance in
switching to new therapy options.
Fibroids are tumors in the uterus which can vary in sizes depending upon the condition and level. A woman
may have one or many fibroids in reproductive organ. It is common for a woman to have multiple fibroid
tumors which are non-cancerous in nature. Uterine fibroids are broadly classified into four categories i.e.
Subserosal fibroids, Intramural fibroids, Submucosal fibroid, and Pedunculated submucosal fibroid.
Complete report available at http://www.marketreportsonline.com/570256.html